PCR Firm QuantaLife Raises $17.2M in Series B | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PCR technology development company QuantaLife announced late Friday that it had closed on a Series B financing round, raising $17.2 million.

The majority of the funds will be used to create a commercialization operation to launch its Droplet Digital PCR platform for the research market and to accelerate development of targeted diagnostic tests, the Pleasanton, Calif.-based company said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.